BioAtla Stock Price, News & Analysis (NASDAQ:BCAB) $1.37 -0.40 (-22.60%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$1.35▼$1.7850-Day Range$1.27▼$1.9852-Week Range$1.24▼$10.83Volume1.78 million shsAverage Volume501,843 shsMarket Capitalization$65.68 millionP/E RatioN/ADividend YieldN/APrice Target$14.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media BioAtla MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside980.3% Upside$14.80 Price TargetShort InterestBearish8.59% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.98Based on 3 Articles This WeekInsider TradingAcquiring Shares$5,080 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.75) to ($2.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.25 out of 5 starsMedical Sector343rd out of 952 stocksBiological Products, Except Diagnostic Industry55th out of 155 stocks 3.5 Analyst's Opinion Consensus RatingBioAtla has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.80, BioAtla has a forecasted upside of 980.3% from its current price of $1.37.Amount of Analyst CoverageBioAtla has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted8.59% of the outstanding shares of BioAtla have been sold short.Short Interest Ratio / Days to CoverBioAtla has a short interest ratio ("days to cover") of 12.1, which indicates bearish sentiment.Change versus previous monthShort interest in BioAtla has recently increased by 0.98%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBioAtla does not currently pay a dividend.Dividend GrowthBioAtla does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BCAB. Previous Next 3.9 News and Social Media Coverage News SentimentBioAtla has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for BioAtla this week, compared to 1 article on an average week.Search Interest15 people have searched for BCAB on MarketBeat in the last 30 days. MarketBeat Follows66 people have added BioAtla to their MarketBeat watchlist in the last 30 days. This is an increase of 187% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioAtla insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,080.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.38% of the stock of BioAtla is held by insiders.Percentage Held by Institutions71.67% of the stock of BioAtla is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for BioAtla are expected to grow in the coming year, from ($2.75) to ($2.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioAtla is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioAtla is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioAtla has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About BioAtla Stock (NASDAQ:BCAB)BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and head and neck cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.Read More BCAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCAB Stock News HeadlinesDecember 4, 2023 | msn.comBCAB, DUNE and CDT among mid-day moversNovember 30, 2023 | finance.yahoo.comBioAtla to Participate in the JMP Securities Hematology and Oncology SummitDecember 4, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 28, 2023 | finance.yahoo.comBioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLCNovember 12, 2023 | finance.yahoo.comBioAtla, Inc. (NASDAQ:BCAB) Q3 2023 Earnings Call TranscriptNovember 9, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BioAtla (BCAB) and Silk Road Medical (SILK)November 8, 2023 | morningstar.comBioAtla Inc Ordinary Shares BCABNovember 7, 2023 | finance.yahoo.comBioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent ProgressDecember 4, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.October 20, 2023 | finance.yahoo.comWe're Keeping An Eye On BioAtla's (NASDAQ:BCAB) Cash Burn RateOctober 17, 2023 | markets.businessinsider.comPromising Outlook for BioAtla’s ADCs in NSCLC Treatment Bolsters Buy RatingOctober 13, 2023 | markets.businessinsider.comBioAtla Inc Registered Shs hosts conference call for investorsOctober 12, 2023 | finance.yahoo.comBioAtla’s Jay M. Short, Ph.D., Selected for The Explorers Club Lowell Thomas AwardSeptember 25, 2023 | markets.businessinsider.comAnalyst Ratings for BioAtlaSeptember 6, 2023 | finance.yahoo.comBioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 3, 2023 | finance.yahoo.comBioAtla to Participate in Upcoming Investor Conferences in AugustAugust 3, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BioAtla (BCAB), Exelixis (EXEL) and Steris (STE)August 3, 2023 | msn.comJP Morgan Maintains BioAtla (BCAB) Overweight RecommendationAugust 3, 2023 | msn.comJMP Securities Reiterates BioAtla (BCAB) Market Outperform RecommendationAugust 3, 2023 | finance.yahoo.comBioAtla, Inc. (NASDAQ:BCAB) Q2 2023 Earnings Call TranscriptAugust 2, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on BioAtla (BCAB)August 1, 2023 | finance.yahoo.comBioAtla Reports Second Quarter 2023 Financial Results and Highlights Recent ProgressJuly 25, 2023 | finance.yahoo.comBioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023July 7, 2023 | finance.yahoo.comWith 51% ownership of the shares, BioAtla, Inc. (NASDAQ:BCAB) is heavily dominated by institutional ownersJuly 6, 2023 | msn.comBioAtla (BCAB) Price Target Increased by 9.33% to 16.73June 26, 2023 | finance.yahoo.comBioAtla Added to Membership of U.S. Small-Cap Russell 2000® IndexMay 31, 2023 | finance.yahoo.comBioAtla to Participate in the Jefferies Healthcare ConferenceSee More Headlines Receive BCAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioAtla and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/04/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BCAB CUSIPN/A CIK1826892 Webwww.bioatla.com Phone858-558-0708FaxN/AEmployees66Year FoundedN/APrice Target and Rating Average Stock Price Target$14.80 High Stock Price Target$25.00 Low Stock Price Target$10.00 Potential Upside/Downside+980.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-106,480,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-89.27% Return on Assets-65.19% Debt Debt-to-Equity RatioN/A Current Ratio4.14 Quick Ratio4.14 Sales & Book Value Annual Sales$250,000.00 Price / Sales262.71 Cash FlowN/A Price / Cash FlowN/A Book Value$3.79 per share Price / Book0.36Miscellaneous Outstanding Shares47,940,000Free Float43,919,000Market Cap$65.68 million OptionableNot Optionable Beta0.69 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Jay M. Short Ph.D. (Age 65)Co-Founder, CEO & Chairman Comp: $1.06MMr. Richard A. Waldron (Age 69)Senior VP & CFO Comp: $617.62kDr. Eric L. Sievers M.D. (Age 59)Chief Medical Officer Comp: $608.18kMr. Christian J. Vasquez (Age 47)Senior VP of Finance, Corporate Controller & Secretary Comp: $408.75kLisa M. PeltonAccounting ManagerMs. Susie MelodySenior Vice President of Human ResourcesDr. Cathy Chang Ph.D.Senior Vice President of Research & DevelopmentDr. Gerhard Frey Ph.D.Senior Vice President of Technology DevelopmentMs. Monica SullivanSenior Vice President of Intellectual Property & ContractsMs. Sheri LydickChief Commercial OfficerMore ExecutivesKey CompetitorsTourmaline BioNASDAQ:TRMLC4 TherapeuticsNASDAQ:CCCCaTyr PharmaNASDAQ:LIFEJasper TherapeuticsNASDAQ:JSPRJATT AcquisitionNYSE:JATTView All CompetitorsInsiders & InstitutionsAmerican Century Companies Inc.Bought 6,410 shares on 11/30/2023Ownership: 0.052%Deutsche Bank AGSold 413,268 shares on 11/24/2023Ownership: 0.582%Adage Capital Partners GP L.L.C.Sold 98,794 shares on 11/15/2023Ownership: 3.757%Affinity Asset Advisors LLCSold 145,000 shares on 11/15/2023Ownership: 0.377%Toroso Investments LLCBought 71,859 shares on 11/15/2023Ownership: 0.335%View All Insider TransactionsView All Institutional Transactions BCAB Stock Analysis - Frequently Asked Questions Should I buy or sell BioAtla stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioAtla in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BCAB shares. View BCAB analyst ratings or view top-rated stocks. What is BioAtla's stock price target for 2024? 5 Wall Street analysts have issued 12 month target prices for BioAtla's shares. Their BCAB share price targets range from $10.00 to $25.00. On average, they anticipate the company's share price to reach $14.80 in the next year. This suggests a possible upside of 980.3% from the stock's current price. View analysts price targets for BCAB or view top-rated stocks among Wall Street analysts. How have BCAB shares performed in 2023? BioAtla's stock was trading at $8.25 on January 1st, 2023. Since then, BCAB stock has decreased by 83.4% and is now trading at $1.37. View the best growth stocks for 2023 here. When is BioAtla's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our BCAB earnings forecast. How were BioAtla's earnings last quarter? BioAtla, Inc. (NASDAQ:BCAB) announced its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.70) EPS for the quarter, topping analysts' consensus estimates of ($0.77) by $0.07. What ETF holds BioAtla's stock ? Formidable ETF holds 88,435 shares of BCAB stock, representing 0.77% of its portfolio. When did BioAtla IPO? (BCAB) raised $150 million in an IPO on Wednesday, December 16th 2020. The company issued 9,400,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies, Credit Suisse and BTIG served as the underwriters for the IPO. Who are BioAtla's major shareholders? BioAtla's stock is owned by many different retail and institutional investors. Top institutional shareholders include Adage Capital Partners GP L.L.C. (3.76%), Vontobel Holding Ltd. (1.50%), Sectoral Asset Management Inc. (1.48%), Vivo Capital LLC (1.12%), Massachusetts Financial Services Co. MA (1.11%) and Northern Trust Corp (0.75%). Insiders that own company stock include Christian Vasquez, Cormorant Asset Management, Lp, Eric Sievers, Guy Levy, Jay M Phd Short, Lawrence Steinman, Richard A Waldron, Scott Andrew Smith and Sylvia Mcbrinn. View institutional ownership trends. How do I buy shares of BioAtla? Shares of BCAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:BCAB) was last updated on 12/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.